Show simple item record

dc.contributor.authorYoung, K
dc.contributor.authorLawlor, RT
dc.contributor.authorRagulan, C
dc.contributor.authorPatil, Y
dc.contributor.authorMafficini, A
dc.contributor.authorBersani, S
dc.contributor.authorAntonello, D
dc.contributor.authorMansfield, D
dc.contributor.authorCingarlini, S
dc.contributor.authorLandoni, L
dc.contributor.authorPea, A
dc.contributor.authorLuchini, C
dc.contributor.authorPiredda, L
dc.contributor.authorKannan, N
dc.contributor.authorNyamundanda, G
dc.contributor.authorMorganstein, D
dc.contributor.authorChau, I
dc.contributor.authorWiedenmann, B
dc.contributor.authorMilella, M
dc.contributor.authorMelcher, A
dc.contributor.authorCunningham, D
dc.contributor.authorStarling, N
dc.contributor.authorScarpa, A
dc.contributor.authorSadanandam, A
dc.date.accessioned2020-09-14T13:45:19Z
dc.date.issued2020-09-03
dc.identifier.citationGut, 2020
dc.identifier.issn0017-5749
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4063
dc.identifier.eissn1468-3288
dc.identifier.doi10.1136/gutjnl-2020-321016
dc.description.abstractOBJECTIVE: A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify potential therapeutic vulnerabilities in this disease. DESIGN: Differential expression analysis of 600 immune-related genes was performed on 207 PanNET samples, comprising a training cohort (n=72) and two validation cohorts (n=135) from multiple transcriptome profiling platforms. Different immune-related and subtype-related phenotypes, cell types and pathways were investigated using different in silico methods and were further validated using spatial multiplex immunofluorescence. RESULTS: The study identified an immune signature of 132 genes segregating PanNETs (n=207) according to four previously defined molecular subtypes: metastasis-like primary (MLP)-1 and MLP-2, insulinoma-like and intermediate. The MLP-1 subtype (26%-31% samples across three cohorts) was strongly associated with elevated levels of immune-related genes, poor prognosis and a cascade of tumour evolutionary events: larger hypoxic and necroptotic tumours leading to increased damage-associated molecular patterns (viral mimicry), stimulator of interferon gene pathway, T cell-inflamed genes, immune checkpoint targets, and T cell-mediated and M1 macrophage-mediated immune escape mechanisms. Multiplex spatial profiling validated significantly increased macrophages in the MLP-1 subtype. CONCLUSION: This study provides novel data on the immune microenvironment of PanNETs and identifies MLP-1 subtype as an immune-high phenotype featuring a broad and robust activation of immune-related genes. This study, with further refinement, paves the way for future precision immunotherapy studies in PanNETs to potentially select a subset of MLP-1 patients who may be more likely to respond.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleImmune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
dc.typeJournal Article
dcterms.dateAccepted2020-08-12
rioxxterms.versionofrecord10.1136/gutjnl-2020-321016
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGut
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)
icr.researchteamSystems and Precision Cancer Medicine
icr.researchteamTargeted Therapy
icr.researchteamTranslational Immunotherapy
dc.contributor.icrauthorRagulan, Chanthirika
dc.contributor.icrauthorMansfield, David
dc.contributor.icrauthorMelcher, Alan


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0